|
|
Vol. 27.12 – 06 July, 2026
|
|
|
|
|
|
|
|
|
Scientists developed macrophage-preferential ionizable cationic lipid-assisted polymeric nanoparticles to co-deliver mRNAs encoding interferon-γ and a CAR molecule, enabling in vivo engineering of CAR-macrophages with a sustained M1-like phenotype. [ACS Nano]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
|
|
|
Investigators validated MUC16 as a clinically relevant target for bladder cancer, noting enriched expression in tumors recalcitrant to existing therapies. They engineered a second-generation mesothelin-based CAR and demonstrated robust activity across multiple cell lines and patient-derived tumor organoids. [Journal of Experimental Medicine]
|
|
|
|
|
|
Through genome-wide CRISPR/Cas9 screening of CAR-sensitive TP53-wildtype and CAR-resistant TP53-mutated CD19 + B cell acute lymphoblastic leukemia (B-ALL) cell lines, researchers found the fatty acid transport protein 2 (FATP2) is a leukemia-intrinsic mechanism of CAR-T resistance in TP53-mutant B-ALL.
[Leukemia]
|
|
|
|
|
|
Investigators confirmed Mucin1-Thomsen-nouvelle (MUC1-Tn) protein expression in T cell acute lymphoblastic leukemia cell lines and primary patient-derived bone marrow cells and subsequently developed MUC1-Tn-targeted CAR T cells.
[Leukemia]
|
|
|
|
|
|
Scientists found that anti-IL1RAP-CAR-NK cells significantly and specifically enhance NK cytotoxicity in vitro and decrease tumor growth and lung metastasis in vivo against IL1RAP+ Ewing sarcoma.
[Journal for Immunotherapy of Cancer]
|
|
|
|
|
|
The authors evaluated the O-glycosylated IIICS domain of fibronectin as a CAR T cell target. FDC6-BBζ and 5E5-BBζ CAR T cells achieved durable tumor control with increased intratumoral CD3⁺ infiltration and reduced tumor-collagen overlap [Cancer Immunology Research]
|
|
|
|
|
|
|
|
In vivo engineering technologies that directly deliver CAR genes in situ are emerging as promising approaches to lower costs and simplify manufacturing by bypassing complex ex vivo procedures.
[Signal Transduction and Targeted Therapy]
|
|
|
|
|
|
The authors illustrate the evolving use of cytokines, reveal non-standardized clinical CAR-T cell manufacturing parameters, and summarize preclinical and next-generation concepts, which may improve manufacturing efficiency, cost-effectiveness and therapeutic outcomes. [Nature Biomedical Engineering]
|
|
|
|
|
|
|
|
The US FDA has granted full approval for the immunotherapy afamitresgene autoleucel (Tecelra®, also known as afami-cel) for the treatment of patients with synovial sarcoma.
[Memorial Sloan Kettering Cancer Center]
|
|
|
|
|
|
The US FDA issued a supplemental approval for Casgevy (exagamglogene autotemcel) for patients aged two years and older with either sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent β thalassemia. [US FDA]
|
|
|
|
|
|
|
|
September 15-17, 2026 Boston, Massachusetts, United States
|
|
|
|
|
|
|
|
|
|
|
Baylor College of Medicine – Houston, Texas, United States
|
|
|
|
|
|
|
Baylor College of Medicine – Houston, Texas, United States
|
|
|
|
|
|
|
ETH Zurich – Zurich, Switzerland
|
|
|
|
|
|
|
Singapore-MIT Alliance for Research and Technology – Singapore
|
|
|
|
|
|
|
UCLA – Los Angeles, California, United States
|
|
|
|
|
|